MedTrace Logo

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

NCT00319254 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2013-01-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.

Conditions

  • Breast Neoplasms
  • Neoplasm Metastasis

Interventions

DRUG

SKI-606 (Bosutinib)

SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States
  • Australia
  • France
  • Hong Kong
  • Malta
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319254 on ClinicalTrials.gov